Effect of temperature variation on hospital admissions and outcomes in dogs with myxomatous mitral valve disease and new onset pulmonary edema


Autoři: Carlo Guglielmini aff001;  Marco Baron Toaldo aff002;  Alex Chiesa aff001;  Barbara Contiero aff001;  Michele Berlanda aff001;  Helen Poser aff001
Působiště autorů: Department of Animal Medicine, Production and Health, University of Padua, Padua, Italy aff001;  Department of Veterinary Medical Sciences, Alma Mater Studiorum—University of Bologna, Bologna, Italy aff002
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227807

Souhrn

The effect of seasonal variation on hospital admissions and outcomes in humans with cardiovascular disease and congestive heart failure (CHF) has been described. This study evaluates the effect of temperature variation on admissions and outcomes in dogs with myxomatous mitral valve disease (MMVD) and first onset CHF. Ninety-three client-owned dogs with MMVD and a first occurrence of pulmonary edema were included in this retrospective clinical cohort study. Recorded clinical and echocardiographic variables were accumulated and analyzed with dogs allocated into groups in a temperature-wise manner that considered the mean of the average (Tave) and maximum ambient temperature (Tmax) of the 14 days preceding hospital admission. A survival analysis was also performed. No difference was found in the percentage of dogs decompensating in three different temperature periods (i.e., cold, intermediate, and hot temperature) according to both Tave and Tmax. Dogs developing CHF during the intermediate temperatures according to Tmax died earlier from cardiac-related causes (median survival time 280 days, 95% CI = 147–486 days) compared to those decompensating during hot temperatures (median survival time 518 days, 95% CI = 344–819 days, P = 0.039). However, an effect of the ambient temperature on survival was not confirmed by Cox proportional hazard analysis. In conclusion, this study failed to show that ambient temperature has an effect on the first occurrence of CHF and outcomes in dogs with MMVD.

Klíčová slova:

Atrial fibrillation – Body weight – Dogs – Edema – Hospitals – Pets and companion animals – Seasons – Veterinary diagnostics


Zdroje

1. Borgarelli M, Häggström J. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. Vet Clin Small Anim. 2010;40: 651–663.

2. Borgarelli M, Buchanan JW. History review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol. 2012;14: 93–101. doi: 10.1016/j.jvc.2012.01.011 22386588

3. Parker HG, Kilroy-Glynn P. Myxomatous mitral valve disease in dogs: does size matter? J Vet Cardiol. 2012;14: 19–29. doi: 10.1016/j.jvc.2012.01.006 22356836

4. Borgarelli M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008;22: 120–128. doi: 10.1111/j.1939-1676.2007.0008.x 18289298

5. Häggström J, Höglund K, Borgarelli M. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease. J Small Anim Pract. 2009;50 Suppl 1; 25–33.

6. Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract. 2010;51: 84–96. doi: 10.1111/j.1748-5827.2009.00889.x 20070494

7. Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G, Tarducci A, et al. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med. 2012;26: 69–75. doi: 10.1111/j.1939-1676.2011.00860.x 22211523

8. Borgarelli M, Abbott J, Braz-Ruivo L, Chiavegato D, Crosara S, Lamb K, et al. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease. J Vet Intern Med. 2015;29:569–574. doi: 10.1111/jvim.12564 25818210

9. López-Alvarez J, Elliott J, Pfeiffer D, Chang YM, Mattin M, Moonarmart W, et al. Clinical severity score system in dogs with degenerative mitral valve disease. J Vet Intern Med. 2015;29: 575–581. doi: 10.1111/jvim.12544 25818211

10. Sargent J, Muzzi R, Mukherjee R, Somarathne S., Schranz K., Stephenson H, et al. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease. J Vet Cardiol. 2015;17: 1–12. doi: 10.1016/j.jvc.2014.11.001 25586168

11. Nakamura K, Osuga T, Morishita K, Suzuki S, Morita T, Yokoyama N, et al. Prognostic values of left atrial function in dogs with chronic mitral valvular heart disease. J Vet Intern Med. 2014;28: 1746–1752. doi: 10.1111/jvim.12441 25327889

12. Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease. J Vet Cardiol. 2012;14: 269–279. doi: 10.1016/j.jvc.2012.01.009 22366569

13. Kim HT, Han SM, Song WJ, Kim B, Choi M, Yoon J, et al. Retrospective study of degenerative mitral valve disease in small-breed dogs: Survival and prognostic variables. J Vet Sci. 2017;18: 369–376. doi: 10.4142/jvs.2017.18.3.369 28057898

14. Jung SW, Sun W, Griffiths LG, Kittleson MD. Atrial fibrillation as a prognostic indicator in medium to large- sized dogs with myxomatous mitral valvular degeneration and congestive heart failure. J Vet Intern Med. 2016;30: 51–57. doi: 10.1111/jvim.13800 26681398

15. Serres F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, et al. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol. 2009;11: 103–121. doi: 10.1016/j.jvc.2009.07.001 19850546

16. Nakamura K, Morita T, Osuga T, Morishita K, Sasaki N, Ohta H, et al. Prognostic value of right ventricular Tei index in dogs with myxomatous mitral valvular heart disease. J Vet Intern Med. 2016;30: 69–75. doi: 10.1111/jvim.13820 26789419

17. Mattin MJ, Boswood A, Church DB, McGreevy PD, O'Neill DG, Thomson PC, et al. Degenerative mitral valve disease: Survival of dogs attending primary-care practice in England. Prev Vet Med. 2015;122: 436–442. doi: 10.1016/j.prevetmed.2015.05.007 26058819

18. Baron Toaldo M, Romito G, Guglielmini C, Diana A, Pelle NG, Contiero B, et al. Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease. J Vet Intern Med. 2018;32: 914–921. doi: 10.1111/jvim.15093 29572938

19. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. J Vet Intern Med. 1995;9: 243–252. doi: 10.1111/j.1939-1676.1995.tb01075.x 8523321

20. The Improve Study Group. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. J Vet Intern Med. 1995;9: 234–242. doi: 10.1111/j.1939-1676.1995.tb01074.x 8523320

21. Ettinger SJ, Cifelli S, Jernigan AD, Longhofer SL, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc. 1998;213: 1573–1577. 9838955

22. The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol. 1999;1(1): 7–18. doi: 10.1016/S1760-2734(06)70025-X 19081317

23. Häggström J, Boswood A, O’Grady M, Jöns O, Smith S, Swift S, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST Study. J Vet Intern Med. 2008;22: 1124–1135. doi: 10.1111/j.1939-1676.2008.0150.x 18638016

24. Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010;24: 331–341. doi: 10.1111/j.1939-1676.2009.0467.x 20102506

25. Stewart S, McIntyre K, Capewell S, McMurray, JJV. Heart failure in a cold climate. J Am Coll Cardiol 2002;39: 760–766. doi: 10.1016/s0735-1097(02)01685-6 11869838

26. Yamamoto Y, Shirakabe A, Hata N,., Kobayashi N, Shinada T, Tomita K, et al. Seasonal variation in patients with acute heart failure: prognostic impact of admission in the summer. Heart Vessels 2015;30: 193–203. doi: 10.1007/s00380-013-0461-8 24398627

27. Kaneko H, Suzuki S, Goto M, Arita T, Yuzawa Y, Yagi N, et al. Presentations and outcomes of patients with acute decompensated heart failure admitted in the winter season. J Cardiol 2014;64: 470–475. doi: 10.1016/j.jjcc.2014.03.004 24802170

28. Gotsman I, Zwas D, Admon D, Lotan C, Keren A. Seasonal variation in hospital admission in patients with heart failure and its effect on prognosis. Cardiology. 2010;117: 268–274. doi: 10.1159/000323511 21273768

29. Gallerani M, Boari B, Manfredini F, Manfredini R. Seasonal variation in heart failure hospitalization. Clin Cardiol. 2011;34: 389–394. doi: 10.1002/clc.20895 21538387

30. Akintoye E, Briasoulis A, Egbe A, Adegbala O, Alliu S, Sheikh M, et al. Seasonal variation in hospitalization outcomes in patients admitted for heart failure in the United States. Clinical Cardiol. 2017;40: 1105–1111.

31. Steinberg GR, Byron JK, Mahoney MM. A retrospective study of circadian and seasonal presentations of dogs with congestive heart failure: 119 cases (1997–2009). J Vet Emerg Crit Care. 2012;22: 341–346.

32. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, et al. Guidelines for diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23: 1142–1150. doi: 10.1111/j.1939-1676.2009.0392.x 19780929

33. Diana A, Guglielmini C, Pivetta M, Sanacore A, Di Tommaso M, Lord PF, et al. Radiographic features of cardiogenic pulmonary edema in dogs with mitral regurgitation: 61 cases (1998–2007). J Am Vet Med Assoc. 2009;235: 1058–1063. doi: 10.2460/javma.235.9.1058 19878003

34. Cornell CC, Kittleson MD, Della Torre P, Häggström J, Lombard CW, Pedersen HD, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med. 2004;18: 311–321. doi: 10.1892/0891-6640(2004)18<311:asomcm>2.0.co;2 15188817

35. Rishniw M, Erb HN. Evaluation of four 2-dimensional echocardiographic methods of assessing left atrial size in dogs. J Vet Intern Med. 2000;14: 429–435. doi: 10.1892/0891-6640(2000)014<0429:eofemo>2.3.co;2 10935894

36. Kellihan HB, Stepien RL. Pulmonary hypertension in dogs: diagnosis and therapy. Vet Clin North Am Small Anim Pract. 2010;40: 623–641. doi: 10.1016/j.cvsm.2010.03.011 20610015

37. Guglielmini C, Diana A, Pietra M, Di Tommaso M, Cipone M. Use of the vertebral heart score in coughing dogs with chronic degenerative mitral valve disease. J Vet Med Sci. 2009;71: 9–13. doi: 10.1292/jvms.71.9 19194070

38. Johnson LR, Pollard RE. Tracheal collapse and bronchomalacia in dogs: 58 cases (7 /2001-1 /2008). J Vet Intern Med. 2010;24: 298–305. doi: 10.1111/j.1939-1676.2009.0451.x 20051001

39. Ferasin L. Crews L, Biller DS, Lamb KE, Borgarelli M. Risk factors for coughing in dogs with naturally acquired myxomatous mitral valve disease. J Vet Intern Med. 2013;27: 286–292. doi: 10.1111/jvim.12039 23398050

40. Vanasse A, Talbot D, Chebana F, Bélanger D., Blais C., Gamache P et al. Effects of climate and fine particulate matter on hospitalizations and deaths for heart failure in elderly: A population-based cohort study. Environ Int. 2017;106: 257–266. doi: 10.1016/j.envint.2017.06.001 28709636


Článek vyšel v časopise

PLOS One


2020 Číslo 1